SEC Form 4 · accession 0001209191-18-016034

Protagonist Therapeutics, Inc · PTGX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Feb 28, 2018

Accepted (ET)

Mar 2, 2018 · 7:17 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001377121

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Feb 28, 2018	A	9,500	$0.00	A	13,322	D
Common Stock	Mar 2, 2018	M	875	$1.89	A	14,197	D
Common Stock	Mar 2, 2018	S	875	$20.00	D	13,322	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F3	$16.95	Feb 28, 2018	A	56,500	A	—	Feb 27, 2028	Common Stock	56,500	56,500	D
Employee Stock Option (right to buy)^F4	$1.89	Mar 2, 2018	M	875	D	—	Oct 22, 2024	Common Stock	875	9,725	D

F1Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017.
F3The shares underlying this option shall vest as to 25% after one year following the grant date, and the remainder will vest in equal monthly installments over the following three years.
F4The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date.